Millennium Management Discloses 4.3% Stake in Perspective Therapeutics

Key Facts

In a move reflecting growing institutional interest in the healthcare sector, Millennium Management disclosed owning 4.89 million shares in Perspective Therapeutics, representing a 4.3% stake. According to regulatory filings, the Schedule 13G disclosure revealed that the firm and Israel Englander briefly crossed the 5% threshold in late June before reducing their position to the current level. Such disclosures are a regulatory requirement providing transparency on major hedge fund activities when ownership reaches significant levels.

This investment comes at a time when small-cap biotech firms are experiencing sharp volatility, as funds like Millennium seek opportunities in the radiopharmaceutical sector. Compared to peers, companies such as Lantheus Holdings have recently reported strong revenue growth, bolstering optimism toward the broader sector (per market data). Perspective Therapeutics is a player in developing targeted cancer therapies, a field that has attracted substantial investment from top asset managers during the last quarter.